Importantly, these mechanistic studies have been proposed to demonstrate that proteasome inhibition with bortezomib induces a functional state of BRCAness in MM cells and sensitizes them to PARP inhibitors’ activity, ultimately resulting in a contextual synthetic lethality [33]. The gene discussed is PARP1; the disease is Miyoshi myopathy.